Resilience Software Specialist Restrata Secures Growth Investment From SEP
13.2.2025 01:01:00 CET | Business Wire | Press release
Restrata, the operational resilience software and service provider to global enterprises, including some of the world’s largest energy and industrial companies, has raised investment from Scottish Equity Partners (SEP) to meet growing market demand.
The investment will support accelerated product development and AI-powered enhancements as well as expansion of existing operations in North America, Europe, and the Middle East.
Increased adoption of the London-based company’s resilienceOS platform, which helps enterprise clients protect their people, assets and operations globally, saw resilienceOS revenue surge more than 50% in 2024.
Enterprises are increasingly focused on people safety and operational resilience due to unprecedented levels of global uncertainty. In response, business leaders are seeking sophisticated technology to mitigate, manage, and respond to operational disruption while maintaining visibility and control over day-to-day operations. These threats range from localised industrial accidents and targeted physical security issues to large scale political instability and security risks, industrial and road safety, extreme weather and natural disasters, as well as organised crime or lone wolf attacks. Spend on solutions such as resilienceOS is growing rapidly, with the multi-billion-dollar market growing more than 10% each year.
The company has been serving the security and safety needs of organisations operating globally, including in high-risk locations, since 2006. Co-founders Chris St George (Chair) and Botan Osman (CEO) combined their technology, security, military and government experience to create a better way for companies to protect people and operations, powered by software.
“We built resilienceOS to solve the challenge of relying on fragmented security systems to protect people and operations,” said Botan Osman. “Security and resilience teams want to focus on what matters most and need software to act as a force multiplier. Customers, employees, and shareholders expect leaders to adopt technology that safeguards people and protects businesses.”
Chris St George added: “resilienceOS is changing the way the world’s largest companies manage safety and security. In particular, the bespoke functionality designed for the energy sector is transforming duty of care in remote, offshore and high-risk markets — ultimately protecting assets, preventing injury and saving lives.”
Customers now use resilienceOS to power global security operation centres (GSOCS) around the world, managing incidents and crises, protecting global travellers everywhere, enabling people safety, monitoring lone workers, and protecting assets.
“resilienceOS is a fully unified platform, with an open ecosystem, working from a common customer data set to more effectively respond to critical events as they happen. The unified and open nature of the platform is unique in the market, and is the key reason why some of the most complex global customers are now choosing resilienceOS,” Osman continued.
“We are delighted to be partnering with the Restrata team to help build on the business’ current momentum,” added Tim Ankers, Director at SEP. “The company has developed a strong product and international customer base. The market tailwinds are clear and Restrata’s resilienceOS product is uniquely placed to serve the increasingly sophisticated security needs of global enterprises.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212395778/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom